Table 1. Baseline demographic, comorbidity and drug characteristics between the low HRR group and the high HRR group.
| Variables | The low HRR group (< 0.74) (n = 226) |
The high HRR group (≥ 0.74) (n = 358) |
P-value |
| Data are presented as means ± SD or n (%). *Presented as median (interquartile range). AF: atrial fibrillation; HRR: hemoglobin-to-red cell distribution width ratio; STS: the Society of Thoracic Surgeons. | |||
| Demographics | |||
| Age, yrs | 78 ± 8 | 76 ± 8 | 0.001 |
| Male | 87 (38%) | 163 (45%) | 0.094 |
| STS score | 4.8 (3.4–6.8)* | 3.2 (2.2–4.8)* | < 0.001 |
| EuroSCORE II | 7.1 (4.5–10.4)* | 5.3 (3.5–8.3)* | < 0.001 |
| Body mass index, kg/m2 | 28 ± 6 | 29 ± 5 | 0.312 |
| Comorbidities | |||
| Diabetes mellitus | 106 (47%) | 143 (40%) | 0.098 |
| Hypertension | 189 (84%) | 290 (81%) | 0.421 |
| Chronic obstructive pulmonary disease | 57 (25%) | 80 (22%) | 0.425 |
| AF | 61 (27%) | 64 (18%) | 0.009 |
| Previous coronary artery bypass grafting | 37 (16%) | 64 (18%) | 0.639 |
| Previous sternotomy | 47 (21%) | 81 (23%) | 0.603 |
| Previous myocardial infarction | 56 (25%) | 89 (25%) | 0.982 |
| Heart failure | 80 (35%) | 104 (29%) | 0.113 |
| Stroke | 16 (7%) | 22 (6%) | 0.656 |
| Renal replacement therapy | 7 (3%) | 4 (1%) | 0.086 |
| Malignancy | 31 (14%) | 28 (8%) | 0.021 |
| Drugs | |||
| Beta-blockers | 164 (73%) | 251 (70%) | 0.524 |
| Statins | 80 (35%) | 157 (44%) | 0.043 |
| Renin-angiotensin-aldosterone system blockers | 141 (62%) | 238 (66%) | 0.313 |
| Diuretics | 101 (45%) | 114 (32%) | 0.002 |
| Calcium channel blockers | 66 (29%) | 114 (32%) | 0.501 |
| Single antiplatelet therapy | 104 (46%) | 190 (53%) | 0.097 |
| Dual antiplatelet therap | 25 (11%) | 30 (8%) | 0.280 |
| Oral anticoagulants | 71 (31%) | 80 (22%) | 0.015 |